Team developing new drug against leading causes of death—sepsis and ARDS
Scientists at Queen's University Belfast are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in...
View ArticleResearchers report long-term remissions in first personalized cell therapy trial
Eight of 14 patients in the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions...
View ArticleGene therapy doubles survival in recurrent glioblastoma
An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy...
View ArticleFresh insight into rheumatoid arthritis offers hope for transforming patient...
Scientists have discovered what they believe has the potential to prevent the onset of an aggressive and hard-to-treat form of rheumatoid arthritis - a condition that affects 700,000 adults in the UK.
View ArticleBoosting the brain's waste disposal system
Universitätsmedizin Berlin have been investigating the extent to which macrophages, a type of phagocytic immune cell, might be used to eliminate the abnormal protein deposits typically found in the...
View ArticleTougher guidelines on animal research can help quest for cures, study suggests
A study of animal-based research published over the last 70 years suggests that leading scientists could have done more to ensure impartial outcomes; experts hope that guidelines introduced in 2010...
View ArticleFirst patients dosed with 'gene silencing' drug for Huntington's disease
The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today.
View ArticleSex differences in preclinical neuroscience research
A little over a year ago, the NIH Director, Dr. Francis Collins and the Director of NIH Office of Research on Women's Health, Dr. Janine Clayton expressed their concern about the stark imbalance in the...
View ArticleHypoxia-inducible factor-1 dependent nuclear entry of factor inhibiting HIF-1
The role of FIH-1 in the regulation of HIF-1 transcriptional activity has been known for some time, but is limited to the understanding that in the nucleus FIH-1 hydrolyzes asparagine at the C-terminus...
View ArticleVaccine against respiratory syncytial virus shows promise in early trial
Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at...
View ArticleA new target for immuno-oncology therapies
By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their...
View ArticleClinical trial of chikungunya vaccine opens
An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health. Results from an initial trial of the...
View ArticleResearchers 'turn off' most notorious cancer-causing protein
It's known as the most common cancer-causing protein, directly responsible for 30 per cent of all cancers and indirectly involved in virtually all cancers. For over 30 years, scientists have failed to...
View ArticleInnovative trial aims to induce remission of type 2 diabetes
Remission is well-known as the goal in cancer treatment but scientists are discovering it's also an exciting possibility for those with type 2 diabetes.
View ArticleNatural protein points to new inflammation treatment
Increasing the level of a naturally-produced protein, called tristetraprolin (TTP), significantly reduced or protected mice from inflammation, according to researchers at the National Institutes of...
View ArticleCombination drug targeting opioid system may help relieve treatment-resistant...
A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of...
View ArticleResearchers present inner workings of Ebola vaccine trial
An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa—and the approach...
View ArticleBeing overweight linked to poorer memory
Overweight young adults may have poorer episodic memory – the ability to recall past events – than their peers, suggests new research from the University of Cambridge, adding to increasing evidence of...
View ArticleProstate cancer vaccine trial begins at Oxford and Sheffield
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received...
View ArticleNuclear export of opioid growth factor receptor is CRM1 dependent
In a study in the February 2016 Issue (241:3) of Experimental Biology and Medicine researchers at The Pennsylvania State University College of Medicine, led by Dr. Pat McLaughlin, discovered that a...
View Article